Detection of Recurrent Prostate Carcinoma with Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic Acid PET/CT and 111In-capromab Pendetide SPECT/CT

Overview

Journal Radiology

Specialty Radiology

Date 2011 Apr 16

PMID 21493787

Citations 67

Authors

David M Schuster

Bital Savir-Baruch

Peter T Nieh

Viraj A Master

Raghuveer K Halkar

Peter J Rossi

Melinda M Lewis

Jonathon A Nye

Weiping Yu

F DuBois Bowman

Mark M Goodman

Affiliations

Soon will be listed here.

Abstract

Purpose: To compare the diagnostic performance of the synthetic amino acid analog radiotracer anti-1-amino-3-fluorine 18-fluorocyclobutane-1-carboxylic acid (anti-3-(18)F-FACBC) with that of indium 111 ((111)In)-capromab pendetide in the detection of recurrent prostate carcinoma.

Materials And Methods: This prospective study was approved by the institutional review board and complied with HIPAA guidelines. Written informed consent was obtained. Fifty patients (mean age, 68.3 years ± 8.1 [standard deviation]; age range, 50-90 years) were included in the study on the basis of the following criteria: (a) Recurrence of prostate carcinoma was suspected after definitive therapy for localized disease, (b) bone scans were negative, and (c) anti-3-(18)F-FACBC positron emission tomography (PET)/computed tomography (CT) and (111)In-capromab pendetide single photon emission computed tomography (SPECT)/CT were performed within 6 weeks of each other. Studies were evaluated by two experienced interpreters for abnormal uptake suspicious for recurrent disease in the prostate bed and extraprostatic locations. The reference standard was a combination of tissue correlation, imaging, laboratory, and clinical data. Diagnostic performance measures were calculated and tests of the statistical significance of differences determined by using the McNemar χ(2) test as well as approximate tests based on the difference between two proportions.

Results: For disease detection in the prostate bed, anti-3-(18)F-FACBC had a sensitivity of 89% (32 of 36 patients; 95% confidence interval [CI]: 74%, 97%), specificity of 67% (eight of 12 patients; 95% CI: 35%, 90%), and accuracy of 83% (40 of 48 patients; 95% CI: 70%, 93%). (111)In-capromab pendetide had a sensitivity of 69% (25 of 36 patients; 95% CI: 52%, 84%), specificity of 58% (seven of 12 patients; 95% CI: 28%, 85%), and accuracy of 67% (32 of 48 patients; 95% CI: 52%, 80%). In the detection of extraprostatic recurrence, anti-3-(18)F-FACBC had a sensitivity of 100% (10 of 10 patients; 95% CI: 69%, 100%), specificity of 100% (seven of seven patients; 95% CI: 59%, 100%), and accuracy of 100% (17 of 17 patients; 95% CI: 80%, 100%). (111)In-capromab pendetide had a sensitivity of 10% (one of 10 patients; 95% CI: 0%, 45%), specificity of 100% (seven of seven patients; 95% CI: 59%, 100%), and accuracy of 47% (eight of 17 patients; 95% CI: 23%, 72%).

Conclusion: anti-3-(18)F-FACBC PET/CT was more sensitive than (111)In-capromab pendetide SPECT/CT in the detection of recurrent prostate carcinoma and is highly accurate in the differentiation of prostatic from extraprostatic disease.

Supplemental Material: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.11102023/-/DC1.

Citing Articles

Emerging Role of Nuclear Medicine in Prostate Cancer: Current State and Future Perspectives.

Volpe F, Nappi C, Piscopo L, Zampella E, Mainolfi C, Ponsiglione A Cancers (Basel). 2023; 15(19).

PMID: 37835440 PMC: 10571937. DOI: 10.3390/cancers15194746.

PSMA PET imaging in the diagnosis and management of prostate cancer.

Houshmand S, Lawhn-Heath C, Behr S Abdom Radiol (NY). 2023; 48(12):3610-3623.

PMID: 37493837 PMC: 10682054. DOI: 10.1007/s00261-023-04002-z.

An overview of radiolabeled amino acid tracers in oncologic imaging.

Jain S, Dhingra V Front Oncol. 2023; 13:983023.

PMID: 36874105 PMC: 9981995. DOI: 10.3389/fonc.2023.983023.

Application of Metabolic Reprogramming to Cancer Imaging and Diagnosis.

Yang Y, Li C, Cai H, Lin B, Kim C, Chang Y Int J Mol Sci. 2022; 23(24).

PMID: 36555470 PMC: 9782057. DOI: 10.3390/ijms232415831.

Diagnostic accuracy of F-18-Fluorocholine PET/CT and multiparametric MRI for prostate cancer.

Kim J, Song Y, Lee W, Lee H, Hwang S, Hong S Prostate Int. 2022; 10(3):152-157.

PMID: 36225289 PMC: 9520420. DOI: 10.1016/j.prnil.2022.04.003.

References

Schuster D, Votaw J, Nieh P, Yu W, Nye J, Master V . Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007; 48(1):56-63. View

De Visschere P, De Meerleer G, Futterer J, Villeirs G . Role of MRI in follow-up after focal therapy for prostate carcinoma. AJR Am J Roentgenol. 2010; 194(6):1427-33. DOI: 10.2214/AJR.10.4263. View

Briganti A . How to improve the ability to detect pelvic lymph node metastases of urologic malignancies. Eur Urol. 2009; 55(4):770-2. DOI: 10.1016/j.eururo.2009.01.024. View

Takahashi N, Inoue T, Lee J, Yamaguchi T, Shizukuishi K . The roles of PET and PET/CT in the diagnosis and management of prostate cancer. Oncology. 2008; 72(3-4):226-33. DOI: 10.1159/000112946. View

Toth G, Lengyel Z, Balkay L, Salah M, Tron L, Toth C . Detection of prostate cancer with 11C-methionine positron emission tomography. J Urol. 2004; 173(1):66-9. DOI: 10.1097/01.ju.0000148326.71981.44. View

Cohen J, Eastham J, Macchia R . Outcomes following negative prostate biopsy for patients with persistent disease after radiotherapy for prostate cancer. Int Braz J Urol. 2010; 36(1):44-8. DOI: 10.1590/s1677-55382010000100007. View

Pound C, Partin A, Eisenberger M, Chan D, Pearson J, Walsh P . Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999; 281(17):1591-7. DOI: 10.1001/jama.281.17.1591. View

Rouviere O, Vitry T, Lyonnet D . Imaging of prostate cancer local recurrences: why and how?. Eur Radiol. 2009; 20(5):1254-66. DOI: 10.1007/s00330-009-1647-4. View

Kundra V, Silverman P, Matin S, Choi H . Imaging in oncology from the University of Texas M. D. Anderson Cancer Center: diagnosis, staging, and surveillance of prostate cancer. AJR Am J Roentgenol. 2007; 189(4):830-44. DOI: 10.2214/AJR.07.2011. View

10.

Manyak M . Indium-111 capromab pendetide in the management of recurrent prostate cancer. Expert Rev Anticancer Ther. 2008; 8(2):175-81. DOI: 10.1586/14737140.8.2.175. View

11.

Venkitaraman R, Cook G, Dearnaley D, Parker C, Khoo V, Eeles R . Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer. J Med Imaging Radiat Oncol. 2009; 53(3):241-7. DOI: 10.1111/j.1754-9485.2009.02070.x. View

12.

Jhaveri F, Zippe C, Klein E, Kupelian P . Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology. 1999; 54(5):884-90. DOI: 10.1016/s0090-4295(99)00252-6. View

13.

Schoder H, Herrmann K, Gonen M, Hricak H, Eberhard S, Scardino P . 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res. 2005; 11(13):4761-9. DOI: 10.1158/1078-0432.CCR-05-0249. View

14.

McConathy J, Voll R, Yu W, Crowe R, Goodman M . Improved synthesis of anti-[18F]FACBC: improved preparation of labeling precursor and automated radiosynthesis. Appl Radiat Isot. 2003; 58(6):657-66. DOI: 10.1016/s0969-8043(03)00029-0. View

15.

Oyen R, Van Poppel H, Ameye F, Van de Voorde W, Baert A, Baert L . Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients. Radiology. 1994; 190(2):315-22. DOI: 10.1148/radiology.190.2.8284375. View

16.

Hong H, Zhang Y, Sun J, Cai W . Positron emission tomography imaging of prostate cancer. Amino Acids. 2009; 39(1):11-27. PMC: 2883014. DOI: 10.1007/s00726-009-0394-9. View

17.

Mohler J, Bahnson R, Boston B, Busby J, DAmico A, Eastham J . NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010; 8(2):162-200. DOI: 10.6004/jnccn.2010.0012. View

18.

Kahn D, Williams R, Haseman M, Reed N, Miller S, Gerstbrein J . Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol. 1998; 16(1):284-9. DOI: 10.1200/JCO.1998.16.1.284. View

19.

Schettino C, Kramer E, Noz M, Taneja S, Padmanabhan P, Lepor H . Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer. AJR Am J Roentgenol. 2004; 183(2):519-24. DOI: 10.2214/ajr.183.2.1830519. View

20.

Sodee D, Sodee A, Bakale G . Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med. 2006; 37(1):17-28. DOI: 10.1053/j.semnuclmed.2006.07.002. View